$ATNM News

Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutant NSCLC, Supporting Mutation-Agnostic Potential

Actinium Pharma Presents New Data On ATNM-400 In Prostate Cancer At SNMMI 2026 Annual Meeting

Actinium Pharmaceuticals Obtains Two Patent Allowances Spanning Its Actimab-A And Iomab-ACT Programs

Actinium Pharmaceuticals To Reveal ATNM-400 Program Update At SNMMI 2026 Conference on May 31-June 2; Co. Receives NYSE Noncompliance Notice

Actinium Highlights Data Presented At AACR Supporting Transcriptional Reprogramming As Central Mechanism Driving Mutation-Agnostic Anti-Leukemic Activity Of Actimab-A In AML

Actinium Pharma Presents Preclinical Results For ATNM-400 Across Prostate, Lung, And Breast Cancer Models Presented At AACR Annual Meeting

Actinium Pharmaceuticals shares are trading higher after the company announced that two abstracts, on ATNM-400 and Actimab-A, respectively, will be presented at the American Association for Cancer Research Annual Meeting 2026 on April 17-22, 2026.

Actinium Pharmaceuticals shares are trading higher after the company announced that two abstracts, on ATNM-400 and Actimab-A, respectively, will be presented at the American Association for Cancer Research Annual Meeting 2026 on April 17-22, 2026.

Actinium Pharmaceuticals Announces New Pan-Tumor Data Demonstrating Potential Of Its Ac-225 Radiotherapy Platform Across Solid Tumors And Hematologic Malignancies; Data To Be Presented At AACR Annual Meeting On April 21

Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic Oncology Applications At AACR Annual Meeting 2026

Actinium Pharmaceuticals Steve O'Loughlin Resigns As CFO; Sandesh Seth Appointed As CFO

Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Actinium Pharma Advances Solid-Tumor Program With Phase 1 Clinical Trial In South Africa Targeting B7-H3

Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In HR+, HER2+ And Triple-Negative Breast Cancer At SABCS 2025

Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?